# Pancreatic Cancer

Manage pancreatic ductal adenocarcinoma by establishing histology when systemic therapy is planned, defining vascular anatomy and metastatic burden on pancreas-protocol imaging, and selecting surgery-first versus neoadjuvant treatment through multidisciplinary review of resectability and biologic risk.

**Clinical question:** How should physicians stage, classify resectability, and sequence treatment for pancreatic ductal adenocarcinoma?

Updated: 2026-08-24T17:01:00.690014+00:00

## What matters in practice
- Obtain high-resolution pancreas-protocol CT angiography or MRI before treatment to assess metastatic disease, vascular involvement, resectability, and operative planning. [19]
- Classify tumors with no major vascular involvement or metastases as resectable; limited arterial contact of 180° or less or reconstructable portal/superior mesenteric venous involvement supports a borderline-resectable designation. [19]
- Upfront surgery followed by adjuvant chemotherapy remains a standard approach for anatomically resectable disease, whereas borderline-resectable disease should receive neoadjuvant chemotherapy, with or without radiotherapy, before resection is attempted. [19][20]
- For resectable disease, consider neoadjuvant chemotherapy when elevated CA 19-9, suspicious regional nodes, or equivocal radiographic findings suggest biologically higher-risk disease. [19]
- Interpret CA 19-9 as a contextual biomarker rather than a stand-alone diagnostic test; tumors in Lewis antigen Le(a−b−) individuals may not secrete CA 19-9. [8]

## Stage before committing to surgery or systemic therapy

The initial decision is whether disease is potentially curable by multimodality treatment or metastatic and managed primarily with systemic therapy.

Use high-resolution pancreas-protocol CT angiography as the principal preoperative study for local staging, vascular mapping, resectability assessment, and surgical planning; MRI is an alternative or complementary modality when needed for staging clarification. Review images in a pancreas-focused multidisciplinary conference before assigning resectability or scheduling resection. [19][20]

Establish the diagnosis and stage with cross-sectional imaging plus tissue confirmation when neoadjuvant or palliative systemic therapy is planned. Imaging alone may establish a surgical pathway for a clearly resectable pancreatic mass, but treatment sequencing should be revisited if radiographic findings are equivocal, regional adenopathy is suspicious, or CA 19-9 is elevated. [19]

Use CA 19-9 as a baseline disease-burden and longitudinal monitoring adjunct, not as a screening or independent diagnostic test. A normal result does not exclude pancreatic ductal adenocarcinoma because some tumors do not secrete CA 19-9 in patients with Lewis antigen Le(a−b−). Interpret interval values with imaging-based response assessment rather than using marker change alone to declare progression or response. [8]
- Review pancreas-protocol imaging for distant metastases before potentially curative surgery. [19]
- Document arterial and portal-mesenteric venous tumor contact in the staging report because this changes the initial treatment sequence. [19]
- Use RECIST 1.1 CT assessment as a current radiographic monitoring standard during systemic treatment; recognize that imaging can be difficult to interpret in patients receiving immunotherapy. [8]

*Anatomic resectability directs the initial therapeutic sequence. [19][20]*

| Clinical category | Defining imaging features | Initial management implication |
| --- | --- | --- |
| Resectable | No metastases and no major vascular involvement. [19] | Upfront resection is a standard approach, followed by adjuvant chemotherapy; consider neoadjuvant chemotherapy for elevated CA 19-9, suspicious nodes, or equivocal imaging. [19] |
| Borderline resectable | Limited contact of 180° or less with the celiac axis, superior mesenteric artery, common hepatic artery, or inferior vena cava, or reconstructable portal vein/superior mesenteric vein involvement. [19] | Use neoadjuvant chemotherapy, with or without radiotherapy, then reassess for surgical resection. [19][20] |
| Locally advanced | Unresectable because of extensive vascular involvement. [19] | Begin individualized nonsurgical management; radiotherapy may improve local control, and surgery may be considered only in selected patients after downstaging. [19] |
| Metastatic | Distant metastatic disease on staging imaging. [19] | Use systemic therapy as the central treatment modality; surgery is not the routine initial strategy. [19][23] |

## Sequence therapy for anatomically resectable disease

The key choice is surgery-first versus neoadjuvant treatment for patients with technically resectable disease.

For resectable pancreatic ductal adenocarcinoma, surgery-first followed by adjuvant chemotherapy remains a standard pathway. The intent is an R0 resection followed by postoperative systemic treatment; therefore, assess whether the patient can realistically complete multimodality therapy before choosing the sequence. [19][20]

Use neoadjuvant chemotherapy selectively in resectable disease with high-risk biology or uncertain stage, particularly elevated CA 19-9, radiographically suspicious lymphadenopathy, or equivocal imaging findings. This approach may clarify disease trajectory before a major operation, but randomized evidence has not yet conclusively established a survival advantage over surgery-first treatment for all upfront-resectable tumors. [19][14]

After resection, use adjuvant combination chemotherapy when tolerable. Combination regimens including modified FOLFIRINOX and gemcitabine-capecitabine have improved disease-free and overall survival compared with gemcitabine in the postoperative setting. [14]
- Refer all apparently resectable cases for review by pancreatic surgery, medical oncology, radiology, and radiation oncology before finalizing treatment order. [14][19]
- Avoid interpreting a technically operable scan in isolation; elevated CA 19-9, suspicious nodes, and radiographic uncertainty are reasons to discuss preoperative systemic therapy. [19]
- Plan adjuvant therapy before surgery, including postoperative recovery expectations and medical fitness for combination chemotherapy. [14]

### Monitoring after surgery or during perioperative therapy

Monitor with serial clinical assessment, cross-sectional imaging, and CA 19-9 only when the tumor is a known secretor. CT-based RECIST 1.1 assessment remains a standard radiographic framework for response monitoring, while CA 19-9 has biologic limitations and should not replace imaging. [8]

*Factors favoring discussion of neoadjuvant treatment despite anatomically resectable imaging. [19]*

| Finding | Clinical interpretation | Next action |
| --- | --- | --- |
| Elevated CA 19-9 | Higher-risk feature in otherwise resectable disease. [19] | Discuss neoadjuvant chemotherapy in multidisciplinary review. [19] |
| Suspicious lymphadenopathy | Raises concern for higher systemic relapse risk or understaged disease. [19] | Consider preoperative systemic therapy rather than automatic surgery-first management. [19] |
| Equivocal radiographic findings | Creates uncertainty regarding local extent or occult metastatic disease. [19] | Re-review pancreas-protocol imaging and consider neoadjuvant chemotherapy. [19] |

## Use induction therapy before attempted resection in borderline-resectable disease

Vascular anatomy determines whether resection should be immediate, deferred after therapy, or not initially pursued.

Treat borderline-resectable pancreatic cancer with neoadjuvant chemotherapy, potentially followed by chemoradiotherapy, before attempting resection. This applies to limited arterial contact of 180° or less and to portal or superior mesenteric venous involvement that is reconstructable. [19][20]

Reassess after neoadjuvant treatment with repeat pancreas-protocol imaging, clinical status, and tumor-marker trajectory when informative. Surgical exploration is appropriate only when the multidisciplinary team judges that an R0 resection is feasible, including vascular reconstruction when required. [19]

Manage locally advanced disease as unresectable at presentation when extensive vascular involvement precludes resection. Systemic therapy is the primary initial modality; radiotherapy may improve local control, while resection is reserved for selected patients with sufficient downstaging and favorable operative anatomy after treatment. [19]
- Do not equate all venous involvement with unresectability; reconstructable portal vein or superior mesenteric vein involvement is included in the borderline-resectable category. [19]
- Do not proceed directly to surgery for borderline-resectable disease solely because there is no distant metastasis. Neoadjuvant treatment is the recommended sequence. [19][20]
- Re-image after induction therapy before operative planning; response assessment is iterative rather than a one-time staging decision. [24]

*Vascular findings that distinguish borderline-resectable from locally advanced pancreatic cancer. [19]*

| Imaging pattern | Resectability interpretation | Treatment sequence |
| --- | --- | --- |
| Tumor contact of 180° or less with celiac axis, superior mesenteric artery, common hepatic artery, or inferior vena cava | Borderline resectable. [19] | Neoadjuvant chemotherapy with or without radiotherapy, then restaging for possible surgery. [19][20] |
| Reconstructable portal vein or superior mesenteric vein involvement | Borderline resectable. [19] | Neoadjuvant treatment before possible venous resection and reconstruction. [19] |
| Extensive vascular involvement preventing resection | Locally advanced and initially unresectable. [19] | Systemic therapy; consider radiotherapy for local control and surgery only after selected downstaging. [19] |

## Match systemic treatment intensity to stage and functional reserve

Combination cytotoxic therapy is central across disease stages, but its use must account for performance status and treatment toxicity.

For localized disease receiving perioperative treatment, multiagent cytotoxic chemotherapy is integrated with surgery rather than used as an alternative to curative-intent local therapy. Modified FOLFIRINOX is one commonly used combination regimen; full-dose FOLFIRINOX consists of oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 180 mg/m², and fluorouracil 2,400 mg/m², with or without a fluorouracil bolus. [11][14]

For metastatic pancreatic cancer, systemic therapy is the core treatment modality. Treatment selection must account for performance status because chemotherapy toxicity is clinically significant; contemporary trial and guideline frameworks commonly evaluate systemic treatment in patients with ECOG performance status 0-2. [23]

Do not routinely expect benefit from immune-checkpoint therapy in unselected pancreatic ductal adenocarcinoma. Pancreatic cancer is largely resistant to immunotherapy, with reported response rates below 5%; investigational immune, cellular, and molecularly targeted approaches should not displace established stage-directed treatment outside appropriate clinical contexts. [16][17]
- Use performance status as an explicit treatment-selection variable before choosing intensive multidrug chemotherapy. [23]
- Discuss molecularly directed approaches in multidisciplinary oncology care, particularly as targeted therapy development is increasingly focused on KRAS alterations, including KRAS G12C. [15]
- Use CT and CA 19-9, when secreted, to follow treatment; neither modality should be interpreted without clinical context. [8]

### Response assessment

Assess treatment response with serial CT using RECIST 1.1 principles and correlate with symptoms, performance status, and CA 19-9 trends when applicable. CT findings can be misleading during immunotherapy because inflammatory infiltration may resemble progression, although immunotherapy has limited activity in unselected pancreatic ductal adenocarcinoma. [8][16]

*Practical systemic-treatment considerations by clinical setting. [11][14][16][23]*

| Setting | Treatment objective | Decision constraint |
| --- | --- | --- |
| Resectable or borderline-resectable disease | Integrate multiagent chemotherapy with curative-intent resection according to resectability and risk features. [14][19] | Sequence chemotherapy before surgery for borderline-resectable disease; surgery-first remains standard for many resectable tumors. [19][20] |
| Locally advanced disease | Control systemic disease and improve local control; reassess selected patients for conversion to surgery. [19] | Extensive vascular involvement precludes initial resection. [19] |
| Metastatic disease | Systemic disease control and symptom-directed management. [19][23] | Balance multidrug-treatment toxicity against ECOG performance status and patient goals. [23] |
| Unselected PDAC treated with immunotherapy | Routine checkpoint inhibitor monotherapy has limited expected activity. [16] | Reported response rates are below 5%; prioritize established systemic strategies or appropriate trials. [16] |

## Escalate complex anatomy and uncertain staging early

Treatment quality depends on repeated expert reassessment rather than a single imaging interpretation.

Refer patients with borderline-resectable or locally advanced disease to a center with pancreatic surgical, vascular reconstruction, medical oncology, radiation oncology, and dedicated radiology expertise. Focused review of pancreas-protocol CT can change resectability assignment, and multidisciplinary management is central to treatment planning across localized disease states. [20][14]

Reconsider surgery after induction therapy only through iterative multidisciplinary assessment of vascular anatomy, metastatic progression, treatment tolerance, and the prospect of an R0 resection. Approximately 20% of patients undergo surgery overall, underscoring the need to avoid nonbeneficial exploration in persistently unresectable disease. [19]

Use shared decision-making when choosing surgery-first, neoadjuvant, or nonsurgical treatment, explicitly discussing anatomic resectability, likelihood of completing multimodality therapy, performance status, toxicity burden, and the patient's goals. [18][23]
- Request dedicated re-review when an outside CT is not pancreas protocol or when arterial or venous involvement is uncertain. [19][20]
- Escalate high-risk resectable disease for preoperative oncology discussion rather than defaulting directly to surgery. [19]
- Reassess resectability after neoadjuvant treatment instead of relying on the initial staging label. [24]

*Triggers for multidisciplinary reassessment. [19][20][24]*

| Trigger | Why it changes management | Required next step |
| --- | --- | --- |
| Outside or equivocal staging imaging | Resectability classification depends on high-quality vascular assessment. [19][20] | Obtain or review pancreas-protocol CT angiography or MRI with dedicated pancreatic radiology input. [19] |
| Elevated CA 19-9 or suspicious nodes in resectable disease | These are high-risk features that can favor neoadjuvant treatment. [19] | Discuss treatment sequencing before surgical scheduling. [19] |
| Completion of neoadjuvant therapy | Operability may change with treatment response or progression. [24] | Repeat staging and review candidacy for resection in multidisciplinary conference. [24] |
| Extensive vascular involvement | Defines locally advanced disease and makes initial surgery inappropriate. [19] | Initiate nonsurgical therapy and reconsider surgery only after selected downstaging. [19] |

## References
1. European evidence-based guidelines on pancreatic cystic ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2018/03/28/gutjnl-2018-316027.full.pdf
2. European evidence-based guidelines on pancreatic cystic neoplasms | Gut — gut.bmj.com — https://gut.bmj.com/content/67/5/789
3. Multicenter randomized controlled trial of neoadjuvant ... — jitc.bmj.com — https://jitc.bmj.com/content/11/12/e007586
4. Pancreatic Incidentalomas — egastroenterology.bmj.com — https://egastroenterology.bmj.com/content/egastro/2/3/e100082.draft-revisions.pdf
5. Abstracts — gut.bmj.com — https://gut.bmj.com/content/55/suppl_2/a1
6. British Society of Gastroenterology and UK-PSC guidelines ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/68/8/1356.full.pdf
7. Treatment of cholangiocarcinoma in patients with primary ... — egastroenterology.bmj.com — https://egastroenterology.bmj.com/content/egastro/2/1/e100045.full.pdf
8. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer — www.science.org — https://www.science.org/doi/10.1126/sciadv.ads5002
9. Direct detection of early-stage cancers using circulating tumor DNA — www.science.org — https://www.science.org/doi/10.1126/scitranslmed.aan2415
10. Treatment Strategy for Borderline Resectable... : Pancreas — journals.lww.com — https://journals.lww.com/pancreasjournal/fulltext/2016/11000/treatment_strategy_for_borderline_resectable.13.aspx?Ppt=Article%7Cpancreasjournal%3A2016%3A11000%3A00013%7C10.1097%2Fmpa.0000000000000634%7C
11. FOLFIRINOX as Initial Treatment for Localized Pancreatic ... — academic.oup.com — https://academic.oup.com/jnci/article/114/5/695/6528326
12. Oligometastatic pancreatic cancer: current state of ... — academic.oup.com — https://academic.oup.com/oncolo/article/30/6/oyaf154/8169154
13. Cancer of the pancreas: ESMO Clinical Practice Guidelines for ... — academic.oup.com — https://academic.oup.com/annonc/article/26/suppl_5/v56/344501
14. Pancreatic Cancer—Advances in the Last 50 Years : World Journal of Surgery — journals.lww.com — https://journals.lww.com/00008139-202608000-00011
15. Development of targeted therapy for pancreatic... — journals.lww.com — https://journals.lww.com/jpancreatology/fulltext/2026/06000/development_of_targeted_therapy_for_pancreatic.2.aspx
16. KRAS-driven immune exclusion in pancreatic ductal ... — academic.oup.com — https://academic.oup.com/oncolo/article/31/7/oyag160/8699630
17. Role of CAR-T cell therapy in pancreatic cancer:... — journals.lww.com — https://journals.lww.com/jpancreatology/fulltext/2026/03000/role_of_car_t_cell_therapy_in_pancreatic_cancer_.1.aspx
18. ESMO Clinical Practice Guideline: Pancreatic Cancer — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-pancreatic-cancer
19. Multidisciplinary Management of Resectable and Borderline Resectable Pancreatic Cancer: How We Work Together — dailynews.ascopubs.org — https://dailynews.ascopubs.org/do/multidisciplinary-management-resectable-and-borderline-resectable-pancreatic-cancer-we
20. Exploring Perioperative Therapy in Pancreatic Cancer — dailynews.ascopubs.org — https://dailynews.ascopubs.org/do/exploring-perioperative-therapy-pancreatic-cancer
21. Contemporary Multidisciplinary Treatment of Borderline- ... — ascopubs.org — https://ascopubs.org/doi/pdf/10.1200/EDBK-26-515560
22. ESMO/ASCO Recommendations for a Global Curriculum in ... — ascopubs.org — https://ascopubs.org/doi/10.1200/GO.23.00277
23. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study — ascopubs.org — https://ascopubs.org/doi/10.1200/JCO-25-00746
24. Contemporary Multidisciplinary Treatment of Borderline-Resectable and Locally Advanced Pancreatic Adenocarcinoma | American Society of Clinical Oncology Educational Book — ascopubs.org — https://ascopubs.org/doi/10.1200/EDBK-26-515560

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.